Who Paid My Doc
Michael Schaufele
Physical Medicine & Rehabilitation Atlanta, GA Medical Doctor
NPI 1639271331 CMS profile 255176
5671 Peachtree Dunwoody Rd Ste 900, Atlanta, GA 30342
General payments
$19,782
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$159,485
Through program year 2025, Michael Schaufele of Atlanta, GA is reported in the CMS Open Payments database as having received $19,782 across 178 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $159,485 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $204 | 5 | |
| 2024 | General | $401 | 8 | |
| 2023 | General | $708 | 13 | |
| 2022 | General | $5,628 | 30 | |
| 2021 | General | $10,504 | 40 | |
| 2020 | General | $727 | 31 | |
| 2019 | General | $1,610 | 51 |
Beside peers
- Michael Schaufele
- Physical Medicine & Rehabilitation median
- Middle half of Physical Medicine & Rehabilitation
- National median
In program year 2025, general payments to Michael Schaufele were reported at $204. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.
Show as a table
| Year | Michael Schaufele | Physical Medicine & Rehabilitation median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,610 | $133 | $45–$390 | $163 |
| 2020 | $727 | $88 | $29–$272 | $114 |
| 2021 | $10,504 | $116 | $33–$360 | $132 |
| 2022 | $5,628 | $123 | $40–$378 | $149 |
| 2023 | $708 | $131 | $43–$396 | $160 |
| 2024 | $401 | $141 | $45–$409 | $164 |
| 2025 | $204 | $139 | $48–$410 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
703
Drug cost
$5,785
Branded share of claims
2.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gabapentin | Generic | 153 | $1,648 | |
| Celecoxib | Generic | 41 | $698 | |
| Diclofenac Sodium | Generic | 72 | $683 | |
| Pregabalin | Generic | 46 | $677 | |
| Duloxetine Hcl | Generic | 50 | $498 | |
| Meloxicam | Generic | 111 | $383 | |
| Tramadol Hcl | Generic | 76 | $354 | |
| Methylprednisolone | Generic | 51 | $335 | |
| Methocarbamol | Generic | 23 | $158 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 17 | $109 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 56 billing codesPaid by Medicare
$184,105
Medicare patients
551
Services billed
5,311
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 69% | |
| Ischemic heart disease | 31% | |
| Diabetes | 23% | |
| Osteoporosis | 23% | |
| Cancer | 19% | |
| Depression | 18% | |
| Atrial fibrillation | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 60 | 3,040 | $305 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 21 | 21 | $86 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
178 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Physical Medicine & Rehabilitation in Georgia
Erik Shaw
Physical Medicine & Rehabilitation · Atlanta, GA
David Tran
Physical Medicine & Rehabilitation · Alpharetta, GA
Payal Fadia
Physical Medicine & Rehabilitation · Decatur, GA
John Musser
Physical Medicine & Rehabilitation · Stockbridge, GA
Abana Azariah
Physical Medicine & Rehabilitation · Atlanta, GA
Gerald Chai
Physical Medicine & Rehabilitation · Lawrenceville, GA
Related records
Physical Medicine & Rehabilitation in Georgia
Practitioners in the same specialty and state, ranked by reported value.
All Physical Medicine & Rehabilitation
Everyone recorded under this specialty, nationwide.
Doctors in Georgia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.